2024, October 22

Health Canada Approves First and Only Oral Targeted Treatment  for Brain Cancer 

2023, June 5

FDA and EMA Accept Vorasidenib Regulatory Submissions for Marketing Approval of Vorasidenib for the Treatment of IDH-mutant Diffuse Glioma

2024, February 20

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma